Physician profile
Carol Banyas
NPI 1881806313
$1,813.72
in general payments reported to CMS, 2019-2025
10 companies · $831 in 2025
The $831 reported for 2025 was more than what 86% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $34.29 · 2023: $361 · 2024: $251 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $573.49 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $404.87 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neuronetics, INC. | $274.49 | 2021 | |
| Alkermes, INC. | $220.13 | 2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $143.24 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $96.57 | 2021-2022 | |
| Bausch Health US, LLC | $31.21 | 2025 | Wellbutrin |
| Lundbeck LLC | $30.00 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $21.34 | 2024 | |
| Acella Pharmaceuticals, LLC | $18.38 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Banyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.